Related references
Note: Only part of the references are listed.Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan
Duncan B. Richards et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Nazzareno Galie et al.
CIRCULATION (2008)
Endothelin receptor antagonists in pulmonary arterial hypertension
J. Dupuis et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Bosentan is a substrate of human OATP1B1 and OATP1B3:: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin a, rifampicin, and sildenafil
Alexander Treiber et al.
DRUG METABOLISM AND DISPOSITION (2007)
Results of European post-marketing surveillance of bosentan in pulmonary hypertension
M. Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Medical therapy for pulmonary arterial hypertension - Updated ACCP evidence-based clinical practice guidelines
David B. Badesch et al.
CHEST (2007)
In vitro-in vivo correlation of hepatobiliary drug clearance in humans
G. Ghibellini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2
Yuji Mano et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2007)
ARIES-1: A placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension
Ronald J. Oudiz et al.
CHEST (2006)
Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin
Michael J. Gerber et al.
CHEST (2006)
No clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil
Christopher Dufton et al.
CHEST (2006)
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
Robyn J. Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Methods to evaluate biliary excretion of drugs in humans: An updated review
Giulia Ghibellini et al.
MOLECULAR PHARMACEUTICS (2006)
Ambrisentan, a non-peptide endothelin receptor antagonist
Hartmut Vatter et al.
CARDIOVASCULAR DRUG REVIEWS (2006)
Ambrisentan therapy for pulmonary arterial hypertension
N Galié et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Survival with first-line bosentan in patients with primary pulmonary hypertension
VV McLaughlin et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes
DC Kemp et al.
TOXICOLOGICAL SCIENCES (2005)
Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat
A Treiber et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Sitaxsentan therapy for pulmonary arterial hypertension
RJ Barst et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Prognosis of pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines
VV McLaughlin et al.
CHEST (2004)
Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan
L Fouassier et al.
JOURNAL OF HEPATOLOGY (2002)
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole
PLM van Giersbergen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
RN Channick et al.
LANCET (2001)
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions
K Fattinger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A
I Binet et al.
KIDNEY INTERNATIONAL (2000)
Share Paper
